Prognostic significance of sentinel lymph node biopsy in elderly with cutaneous melanoma: systematic review and meta‐analysis

Abstract

AbstractSentinel lymph node biopsy is the most powerful prognostic indicator to date for cutaneous melanoma. Even though elderly patients have a lower incidence of sentinel node involvement, its results are still necessary for access to adjuvant therapies. This is highly relevant considering that the Western population shows an aging trend, and the incidence of melanoma has grown exponentially over the years, making elderly patients more likely to die from melanoma than younger ones. We performed a systematic review to investigate the prognostic significance of sentinel lymph node biopsy in elderly patients with melanoma. The systematic review was conducted following the PRISMA guidelines and registered in PROSPERO. The authors searched the Cochrane Database, EMBASE, PubMed, and WOS. Eligible studies for the systematic review were clinical trials, observational population studies, clinical or hospital‐based cohort studies, and case–control studies. The meta‐analysis was conducted using the R software program applying the meta package. Six reports were identified to meet the inclusion criteria. All studies were retrospective, non‐randomized cohorts. The results obtained in this systematic review show a statistically significant influence of sentinel lymph node biopsy on disease‐specific survival (HR = 2.87; 95% CI: 1.73–4.74) but also suggest that a positive result negatively impacts disease‐free survival (HR = 3.41; 95% CI: 0.96–12.11). This meta‐analysis shows that a positive sentinel lymph node biopsy does not imply differences in overall survival but significantly influences disease‐specific survival and suggests an unfavorable impact on disease‐free survival.